NLS Pharmaceutics Ltd. (NLSP)

NASDAQ: NLSP · IEX Real-Time Price · USD
0.590
-0.019 (-3.18%)
Jun 29, 2022 10:48 AM EDT - Market open
-3.18%
Market Cap 11.54M
Revenue (ttm) n/a
Net Income (ttm) -11.95M
Shares Out 19.56M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,396
Open 0.600
Previous Close 0.609
Day's Range 0.550 - 0.610
52-Week Range 0.460 - 3.720
Beta n/a
Analysts Buy
Price Target 7.65 (+1,196.6%)
Earnings Date Jun 30, 2022

About NLSP

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company... [Read more...]

Industry Biotechnology
IPO Date Jan 29, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NLSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for NLSP stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 1,196.61% from the latest price.

Price Target
$7.65
(1,196.61% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer

ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...

NLS Pharmaceutics Announces Over Enrollment in its Phase 2a Clinical Trial Evaluating Quilience(R) for the Treatment ...

60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022 Nearly 90% of patients...

NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy

Since the interim results were released in March, patient enrollment has nearly doubled Of the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing scr...

NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discover...

NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference

ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and de...

NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discover...

NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery ...

NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives

ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discover...

NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treat...

Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies Product sales through the NPP ar...

NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference

ZURICH, SWITZERLAND / ACCESSWIRE / March 25, 2022 - NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and de...

NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale

NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced interim topline data from its Phase 2a trial of its lead product candidate, Quilience (Mazindol ER), in narcolepsy.  For excessive daytime sleepiness (...

NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy

Clinically meaningful results with Mazindol ER exhibiting a 39% reduction in ESS from baseline (-4.3 points placebo-adjusted); confirms statistical powering of the ongoing Phase 2a trial Safety and tole...

3 Penny Stocks To Watch For Your List In March 2022

Penny stocks for your watch list this month. The post 3 Penny Stocks To Watch For Your List In March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: AKBAGSAT

NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Cha...

ZURICH, SWITZERLAND / ACCESSWIRE / February 25, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP) (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco...

NLS Pharmaceutics to Participate in 2022 BIO CEO & Investor Conference

ZURICH, SWITZERLAND / ACCESSWIRE / February 11, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discov...

Why Are NLS Pharmaceutics Shares Trading Higher During Premarket Monday?

NLS Pharmaceutics Ltd NLSP shares are trading higher after the Company announced to present interim topline data from its Phase 2a trial evaluating its lead product candidate, Quilience (Mazindol ER), f...

NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the ...

Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled 21 clinical sites in the United States actively enrolling patients Nearly 90% of patients completing the tri...

NLS Pharmaceutics Invites Patients, Caregivers and Other Interested Parties to Attend International Narcolepsy Webinar

ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...

3 Penny Stocks to Watch in the Second Week of January

Here are three penny stocks to add to your watchlist for next week The post 3 Penny Stocks to Watch in the Second Week of January appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols: BRFSDTST

NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation

Key patent now granted in major markets including the U.S., Europe, Canada & South Korea Patent claims cover use of the Company's lead product candidate, Quilience® (mazindol ER) in both attention defic...

NLS Pharmaceutics Announces Preclinical Results Confirming the Potential Benefit and Safety Profile of NLS-4 for Circ...

STANS, SWITZERLAND / ACCESSWIRE / November 30, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...

NLS Pharmaceutics CEO Issues Letter to Shareholders

STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove...

NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatig...

STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and d...

NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side

STANS, SWITZERLAND / ACCESSWIRE / September 30, 2021 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and de...